Furubayashi, N., Negishi, T., Yamashita, T., Kusano, S., Taguchi, K., Shimokawa, M., & Nakamura, M. (2017). Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma. Mol Clin Oncol.
Chicago Style aipamenaFurubayashi, Nobuki, Takahito Negishi, Takuya Yamashita, Shuhei Kusano, Kenichi Taguchi, Mototsugu Shimokawa, and Motonobu Nakamura. "Progression-free Survival of First-line Treatment With Molecular-targeted Therapy May Be a Meaningful Intermediate Endpoint for Overall Survival in Patients With Metastatic Renal Cell Carcinoma." Mol Clin Oncol 2017.
MLA aipamenaFurubayashi, Nobuki, et al. "Progression-free Survival of First-line Treatment With Molecular-targeted Therapy May Be a Meaningful Intermediate Endpoint for Overall Survival in Patients With Metastatic Renal Cell Carcinoma." Mol Clin Oncol 2017.